Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
NCT05386108

Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

Led by Stemline Therapeutics, Inc. · Updated on 2026-04-06

73

Participants Needed

86

Research Sites

221 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a multi-site, global, open-label study that includes a phase 1b evaluation of elacestrant in combination with abemaciclib in women and men with brain metastases from estrogen receptor (ER)-positive, human epidermal growth factor receptor-2 (HER-2) negative breast cancer. Phase 1b was designed to select the recommended phase 2 dose (RP2D) and is followed by an ongoing phase 2 evaluation of elacestrant in combination with abemaciclib in participants with active brain metastases from ER-positive, HER-2 negative breast cancer.

CONDITIONS

Official Title

Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Signed informed consent before any study activities
  • Women or men aged 18 years or older
  • Female participants may be postmenopausal or pre/perimenopausal with appropriate hormone therapy
  • ER-positive tumor confirmed by local lab testing with ≥1% staining by immunohistochemistry
  • HER-2 negative tumor confirmed by local lab testing
  • In Phase 2, at least one active and measurable brain metastasis per RECIST 1.1 criteria
  • In Phase 1b, presence of brain metastases allowed but not required; at least one measurable lesion outside the brain required
  • Stable or decreasing corticosteroid dose (≤4 mg dexamethasone daily) for at least 7 days prior to baseline
  • No more than one seizure within 4 weeks before starting therapy
  • Prior metastatic therapy including at least one endocrine therapy, up to two chemotherapy regimens, and up to two lines of prior CDK 4/6 inhibitor excluding abemaciclib
  • Documented intracranial and/or extracranial progression or recurrence after most recent therapy
  • ECOG performance status ≤2
  • Life expectancy of at least 12 weeks
  • Adequate bone marrow and organ function per laboratory values
  • Willingness and ability to follow study visit schedule and protocol requirements
Not Eligible

You will not qualify if you...

  • Need for immediate central nervous system-specific treatment
  • Imminent organ failure or visceral crisis
  • Presence of leptomeningeal metastases
  • Treatment-naïve in advanced/metastatic breast cancer setting
  • History of pulmonary embolism, stroke, or heart attack within 6 months prior to screening
  • Prior abemaciclib therapy in metastatic setting
  • Prior treatment with elacestrant or investigational selective estrogen receptor degraders in metastatic setting
  • Concurrent or recent malignancy within 3 years except certain treated cancers
  • Participation in other breast cancer intervention trials
  • Recent anti-cancer or investigational drug treatment within specified washout periods
  • Radiation therapy within 7 days before first study dose or incomplete recovery from radiation
  • Uncontrolled active infections including detectable hepatitis B or C viral load
  • Major surgery within 4 weeks before starting therapy
  • Inability to take oral medication or uncontrolled gastrointestinal conditions affecting drug absorption
  • Females of childbearing potential not agreeing to use effective contraception or abstain from ova donation
  • Male participants with partners of childbearing potential not agreeing to contraception or sperm restrictions
  • Pregnant or breastfeeding females
  • Known intolerance to study drugs or their ingredients
  • Use of strong/moderate CYP3A4 inducers/inhibitors or certain herbal supplements within specified timeframes
  • Vaccination within 7 days prior to randomization
  • Severe medical or psychiatric conditions preventing study participation

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 86 locations

1

Providence Medical Foundation

Fullerton, California, United States, 92835

Actively Recruiting

2

California Research Institute

Los Angeles, California, United States, 90027

Actively Recruiting

3

Carle Cancer Center

Urbana, Illinois, United States, 61801

Actively Recruiting

4

Dana-Farber Cancer Institute

Boston, Massachusetts, United States, 02215

Actively Recruiting

5

Henry Ford Hospital

Detroit, Michigan, United States, 48202

Actively Recruiting

6

Miami Valley Hospital South

Centerville, Ohio, United States, 45459

Actively Recruiting

7

Oregon Health & Science University

Portland, Oregon, United States, 97239

Completed

8

SCRI Oncology Partners

Nashville, Tennessee, United States, 37203

Actively Recruiting

9

University of Texas MD Anderson Cancer Center

Houston, Texas, United States, 77030

Actively Recruiting

10

UT Health San Antonio University of Texas

San Antonio, Texas, United States, 78229

Completed

11

Virginia Cancer Institute

Norfolk, Virginia, United States, 00115

Actively Recruiting

12

Antwerp University Hospital

Edegem, Belgium, 2650

Actively Recruiting

13

Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg

Leuven, Belgium

Actively Recruiting

14

Universite Catholique de Louvain (UCL) - Cliniques Universitaires Saint-Luc

Woluwe-Saint-Lambert, Belgium

Actively Recruiting

15

Institut de Cancerologie de l'Ouest site Paul Papin

Angers, France

Actively Recruiting

16

Hôpital Morvan - CHRU de Brest - cancérologie et d'hématologie

Brest, France

Actively Recruiting

17

Centre Francois Baclesse - Oncologie Medicale - Cancerolo

Caen, France

Actively Recruiting

18

Centre Jean Perrin

Clermont-Ferrand, France

Actively Recruiting

19

Centre Léon Bérard - Département Oncologie Médicale

Lyon, France

Actively Recruiting

20

Centre de Cancerologie du Grand Montpellier

Montpellier, France, 37070

Actively Recruiting

21

Hôpital de la Pitiê Salpêtriêre

Paris, France, 75103

Actively Recruiting

22

Centre Hospitalier Universitaire de Poitiers

Poitiers, France, 86000

Actively Recruiting

23

Institut Claudius Regaud

Toulouse, France, 31100

Actively Recruiting

24

Klinikum Bayreuth GmbH

Bayreuth, Germany, 95445

Actively Recruiting

25

Uniklinik Koeln - Klinik und Poliklinik fuer Frauenheilkunde

Cologne, Germany

Completed

26

Universitatsklinikum Carl Gustav Carus

Dresden, Germany

Actively Recruiting

27

Universitaetsklinikum Duesseldorf

Düsseldorf, Germany

Actively Recruiting

28

Universitätsklinikum Erlangen

Erlangen, Germany

Actively Recruiting

29

Medizinische Hochschule Hannover

Hanover, Germany

Actively Recruiting

30

Universitätsklinikum Leipzig

Leipzig, Germany

Actively Recruiting

31

Klinikum Worms gGmbH

Worms, Germany, 67550

Actively Recruiting

32

Helios Klinikum Wuppertal

Wuppertal, Germany

Actively Recruiting

33

National and Capodistrian University of Athens - University General Hospital Attikon

Athens, Greece, 12462

Actively Recruiting

34

Metropolitan Hospital [Oncology]

Piraeus, Greece, 12462

Actively Recruiting

35

EUROMEDICA General Clinic of Thessaloniki

Thessaloniki, Greece, 54645

Completed

36

Interbalkan European Medical Center

Thessaloniki, Greece, 57001

Actively Recruiting

37

AOU Ospedali Riuniti Umberto I-G.M.Lancisi -G.Salesi

Ancona, Italy

Actively Recruiting

38

Istituto di Candiolo, IRCCS

Candiolo, Italy

Actively Recruiting

39

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori - IRST IRCCS

Meldola, Italy

Actively Recruiting

40

A. O. Ospedali Riuniti Parpardo, Piemonte, Messina

Messina, Italy

Actively Recruiting

41

IEO - Istituto Europeo di Oncologia, IRCCS

Milan, Italy

Actively Recruiting

42

Azienda Ospedaliero-Universitaria di Modena, Policlinico di Modena

Modena, Italy

Actively Recruiting

43

Ospedale San Gerardo, ASST di Monza, IRCCS

Monza, Italy

Actively Recruiting

44

Azienda Ospedaliera Universitaria Federico II

Naples, Italy

Actively Recruiting

45

Istituto Nazionale dei Tumori - Fondazione Pascale, IRCCS

Naples, Italy

Actively Recruiting

46

Istituto Oncologico Veneto IOV - IRCCS

Padova, Italy

Actively Recruiting

47

IRCCS Policlinico San Matteo, Università degli studi di Pavia, Pavia Fondazione IRCCS Policlinico San Matteo

Pavia, Italy

Actively Recruiting

48

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Roma, Italy

Actively Recruiting

49

Azienda Ospedaliera Santa Maria di Terni

Terni, Italy

Actively Recruiting

50

AOU Città della Salute e della Scienza di Torino, Ospedale Molinette

Torino, Italy

Actively Recruiting

51

Asan Medical Center

Seoul, South Korea, 05505

Actively Recruiting

52

Gangnam Severance Hospital

Seoul, South Korea, 06273

Actively Recruiting

53

Samsung Medical Center

Seoul, South Korea, 06351

Actively Recruiting

54

Ewha Womans University MokDong Hospital

Seoul, South Korea, 07985

Actively Recruiting

55

Seoul National University Bundang Hospital

Seoul, South Korea

Actively Recruiting

56

Seoul National University Hospital

Seoul, South Korea

Actively Recruiting

57

University Hospital Reina Sofía

Córdoba, Andalusia, Spain, 14004

Actively Recruiting

58

University Hospital Ramón y Cajal

Madrid, Madrid, Spain, 28034

Actively Recruiting

59

University Hospital 12 de Octubre

Madrid, Madrid, Spain, 28041

Actively Recruiting

60

Clara Campal Comprehensive Cancer Center (CIOCC)

Madrid, Madrid, Spain, 28050

Actively Recruiting

61

University Clinical Hospital Virgen de la Arrixaca

El Palmar, Murcia, Spain, 30120

Actively Recruiting

62

Hospital Clinic De Barcelona

Barcelona, Spain, 08036

Actively Recruiting

63

Hospital Universitari Vall D Hebron

Barcelona, Spain

Actively Recruiting

64

Clinica Universidad de Navarra

Madrid, Spain

Actively Recruiting

65

Hospital Clínico San Carlos

Madrid, Spain

Actively Recruiting

66

Hospital Universitario Quirónsalud Madrid

Madrid, Spain

Actively Recruiting

67

Clinica Universidad de Navarra

Pamplona, Spain

Actively Recruiting

68

Complexo Hospitalario Universitario De Santiago

Santiago de Compostela, Spain, 15706

Actively Recruiting

69

Fundación Instituto Valenciano De Oncología

Valencia, Spain

Actively Recruiting

70

Hospital Universitario Virgen del Rocío

Valencia, Spain

Actively Recruiting

71

Adana Sehir Hastanesi

Adana, Turkey (Türkiye)

Actively Recruiting

72

Ankara Bilkent Sehir Hastanesi Tibbi Onkoloji Klinigi

Ankara, Turkey (Türkiye)

Actively Recruiting

73

Ankara University Medical Faculty

Ankara, Turkey (Türkiye)

Actively Recruiting

74

Dr. Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve Arastirma Hastanesi

Ankara, Turkey (Türkiye)

Actively Recruiting

75

Gulhane Egitim ve Arastirma Hastanesi Tibbi Onkoloji Klinigi

Ankara, Turkey (Türkiye)

Actively Recruiting

76

Hacettepe University Medical Faculty

Ankara, Turkey (Türkiye)

Actively Recruiting

77

Memorial Ankara Hastanesi Tibbi Onkoloji

Ankara, Turkey (Türkiye)

Actively Recruiting

78

Ege University Medical Faculty

Bornova, Turkey (Türkiye)

Actively Recruiting

79

Acibadem Altunizade Hospital

Istanbul, Turkey (Türkiye)

Actively Recruiting

80

Medipol Mega Hospital - Medical Oncology

Istanbul, Turkey (Türkiye)

Actively Recruiting

81

Prof. Dr. Suleyman Yalcin Sehir Hastanesi

Istanbul, Turkey (Türkiye)

Actively Recruiting

82

University Hospitals of Leicester NHS Trust -Glenfield Hospital

Leicester, United Kingdom

Withdrawn

83

The Clatterbridge Cancer Centre NHS Foundation Trust

Liverpool, United Kingdom

Withdrawn

84

Guy's and St Thomas' NHS Foundation Trust

London, United Kingdom

Actively Recruiting

85

University College London Hospitals NHS Foundation Trust - University College Hospital (UCH) - Macmillan Cancer Centre

London, United Kingdom

Actively Recruiting

86

The Christie NHS Foundation Trust - Medical Oncology

Manchester, United Kingdom, M20 4BX

Actively Recruiting

Loading map...

Research Team

S

Stemline Trials

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

SEQUENTIAL

Primary Purpose

TREATMENT

Number of Arms

4

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer | DecenTrialz